Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00940498 · ClinicalTrials.gov registry record · Phase 1
Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT00940498 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 78 participants.
The verdict
NCT00940498, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
This is a two-part study of a compound called PF-05212384 (also known as PKI-587). The purpose of part 1 is to identify the Maximum Tolerated Dose (MTD) of PF-05212384 using a Continual Reassessment Method (CRM). Part 1 will include subjects with any solid tumor. In Part 2 two cohorts will be enrolled. One cohort will assess safety, tolerability and preliminary efficacy in 20 subjects at the MTD and will include subjects with breast cancer, ovarian cancer, endometrial cancer, colorectal cancer renal cancer or glioblastoma (a type of brain tumor). The other cohort will include 5 to 15 subjects with any type of tumor who consent to provide tumor biopsies while participating in the study.
Interventions
- DRUG PF-05212384 (also known as PKI-587)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00940498
The ClinicalTrials.gov registry entry for NCT00940498 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-05212384 (also known as PKI-587) is the first listed.
NCT00940498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00940498 about?
NCT00940498 is a clinical study titled "Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors". This is a two-part study of a compound called PF-05212384 (also known as PKI-587). The purpose of part 1 is to identify the Maximum Tolerated Dose (MTD) of PF-05212384 using a Continual Reassessment Method (CRM). Part 1 will include subjects with any solid tumor. In Part 2 two cohorts will be enroll...
What is the current status of trial NCT00940498?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2010-01. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00940498?
The interventions under investigation include: PF-05212384 (also known as PKI-587) (DRUG).
Who is sponsoring clinical trial NCT00940498?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.